Literature DB >> 11017843

Treatment of latent tuberculosis infection in patients aged > or =35 years.

S A Gilroy1, M A Rogers, D C Blair.   

Abstract

Treating patients aged > or =35 years for tuberculosis infection has been controversial because of the hepatotoxic effects of isoniazid. A 2-year retrospective cohort study of outpatient medical records determined the completion rate in this age group and identified risk factors associated with isoniazid-associated hepatotoxicity. Isoniazid preventative therapy was well tolerated. However, toxicity occurred in women receiving concomitant medications and men who used alcohol.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11017843     DOI： 10.1086/314037

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  10 in total

1.  Screening of imported infectious diseases among asymptomatic sub-Saharan African and Latin American immigrants: a public health challenge.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez; Francesca F Norman; Federico Ferrere-González; Ángela Martínez-Pérez; José Antonio Pérez-Molina
Journal:  Am J Trop Med Hyg       Date:  2015-02-02       Impact factor: 2.345

Review 2.  Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas.

Authors:  Victoria O Kasprowicz; Gavin Churchyard; Stephen D Lawn; S Bertel Squire; Ajit Lalvani
Journal:  J Infect Dis       Date:  2011-11-15       Impact factor: 5.226

3.  Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.

Authors:  April C Pettit; James Bethel; Yael Hirsch-Moverman; Paul W Colson; Timothy R Sterling
Journal:  J Infect       Date:  2013-07-08       Impact factor: 6.072

4.  Tuberculosis Prevention in the Private Sector: Using Claims-Based Methods to Identify and Evaluate Latent Tuberculosis Infection Treatment With Isoniazid Among the Commercially Insured.

Authors:  Erica L Stockbridge; Thaddeus L Miller; Erin K Carlson; Christine Ho
Journal:  J Public Health Manag Pract       Date:  2018 Jul/Aug

Review 5.  Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries.

Authors:  Jonathon R Campbell; David Dowdy; Kevin Schwartzman
Journal:  PLoS Med       Date:  2019-06-06       Impact factor: 11.069

6.  Isoniazid Toxicity among an Older Veteran Population: A Retrospective Cohort Study.

Authors:  Christopher Vinnard; Anand Gopal; Darren R Linkin; Joel Maslow
Journal:  Tuberc Res Treat       Date:  2013-01-10

7.  The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection.

Authors:  Mariangela Atteno; Luisa Costa; Alessandro Matarese; Francesco Caso; Antonio Del Puente; Luca Cantarini; Maria Luisa Bocchino; Alessandro Sanduzzi; Raffaele Scarpa
Journal:  Clin Rheumatol       Date:  2014-02-21       Impact factor: 2.980

Review 8.  Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review.

Authors:  Anke L Stuurman; Marije Vonk Noordegraaf-Schouten; Femke van Kessel; Anouk M Oordt-Speets; Andreas Sandgren; Marieke J van der Werf
Journal:  BMC Infect Dis       Date:  2016-06-08       Impact factor: 3.090

9.  Initiation and completion rates for latent tuberculosis infection treatment: a systematic review.

Authors:  Andreas Sandgren; Marije Vonk Noordegraaf-Schouten; Femke van Kessel; Anke Stuurman; Anouk Oordt-Speets; Marieke J van der Werf
Journal:  BMC Infect Dis       Date:  2016-05-17       Impact factor: 3.090

10.  Testing and treatment for latent tuberculosis infection in people living with HIV and substance dependence: a prospective cohort study.

Authors:  Tessa Runels; Elizabeth J Ragan; Alicia S Ventura; Michael R Winter; Laura F White; C Robert Horsburgh; Jeffrey H Samet; Richard Saitz; Karen R Jacobson
Journal:  BMJ Open       Date:  2022-03-10       Impact factor: 2.692
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.